HCPLive 5 Stories in Under 5: Week of 02/15
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy
Obinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.